Related Experiment Video
Updated: Aug 19, 2026
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
[Treatment of severe acquired aplastic anemia]
1Haematologisk afd, Rigshospitalet, København.
Insights
Severe acquired aplastic anaemia requires prompt treatment. Early bone marrow transplant is preferred for younger patients with a matched sibling, while others benefit from immunosuppression, with transplant considered for non-responders.
Area of Science:
- Hematology
- Immunology
- Transplantation Medicine
Context:
- Severe acquired aplastic anaemia presents significant morbidity and mortality.
- Current treatments include bone marrow transplantation and immunosuppressive therapy.
- Treatment decisions are guided by patient age, neutrophil count, and donor availability.
Purpose:
- To outline current treatment strategies for severe acquired aplastic anaemia.
- To differentiate treatment approaches based on patient-specific factors.
- To highlight the role of bone marrow transplantation and immunosuppression.
Summary:
- For patients under 45 with a neutrophil granulocyte count <0.5 x 10(9)/L and an HLA-identical sibling, early bone marrow transplantation is the primary choice.
- Alternative treatment involves immunosuppression (antithymocyte globulin, cyclosporin, glucocorticoid, G-CSF).
- Bone marrow transplantation may be considered for non-responders to immunosuppression if a donor is available; unrelated donor transplants remain experimental.
Impact:
- Establishes evidence-based guidelines for managing severe aplastic anaemia.
- Improves patient outcomes by optimizing treatment selection.
- Informs future research directions, particularly in unrelated donor transplantation.
Abstract:
Severe acquired aplastic anaemia is associated with high morbidity and mortality despite improvement in the results obtained both with bone marrow transplantation and with immunosuppressive treatment. Early bone marrow transplantation is the treatment of choice for patients under 45 years of age, if the neutrophil granulocyte count is less than 0.2-0.5 x 10(9)/l and an HLA-identical sibling donor is available. Other patients should receive primary immunosuppression with antithymocyte globulin, cyclosporin and glucocorticoid in combination with granulocyte colony-stimulating factor. If they fail to respond after three months, and a donor is available, such patients may be treated with bone marrow transplantation. However, transplantation with marrow from donors other than HLA-identical siblings is still at an experimental stage.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...